RNL Bio, a South Korean biotech company, is venturing into the world of treating human diseases through stem cell therapies, raising the prospects of a new, highly profitable export industry.

The company, famous for the commercial cloning of dogs, is developing therapies using adult stem cells to treat degenerative diseases – a fledgling industry that could open up a $15bn market by 2012.